Allergy Therapeutics PLC (AGY)

ORD 0.1P

Sell: 10.50p|Buy: 12.00p|Change: 0.30 (-2.54%)

Open

11.25p

Previous close

11.80p

Trade high

11.90p

Volume

224,890

Year high

12.00p

Year low

5.00p

Dividend yield

–

Market capitalisation

£706.27 mn

P/E ratio

49.50

ISIN

GB00B02LCQ05

This share can be held in a Dealing account Stocks and shares ISA Lifetime ISA JISA SIPPand can be used with Dividend reinvestment

Share price

Performance 19/12/2025

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann

	Total return (%)
Allergy Therapeutics PLC	- 2.54
More...

Company profile

Allergy Therapeutics plc is an international biotechnology group focused on the diagnosis and treatment of allergic disorders through immunotherapies that target the underlying cause of disease. Its portfolio includes Pollinex, Pollinex Quattro, Acarovac, Tyrosine S/TU, Venomil, Oralvac and other allergy immunotherapy products, supported by R&D programmes such as Grass MATA MPL and VLP Peanut. The Group operates in a single class of business, being the manufacture and sale of allergy-related medicines, and maintains centralised manufacturing and research and development capabilities in the UK. Its geographical presence covers Central Europe (Germany, Austria, Switzerland and the Netherlands), Southern Europe (Spain and Italy) and the Rest of the World (including the UK).

Sector

Healthcare

News

Recent trades

Date	Time	Price	Quantity	Value (£)
19/12/2025	04:35:25	11.5	10,050	1,155.75
19/12/2025	03:18:31	11.275	35,000	3,946.25
19/12/2025	02:44:31	11.775	42,361	4,988.01
19/12/2025	02:44:03	11.2222	300	33.67
19/12/2025	02:00:20	11.7	2,000	234.00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.